March 2, 2018 -- VIENNA - The debate over the safety of gadolinium-based contrast agents for MRI shows no sign of going away, and U.S.-style lawsuits filed against radiologists and vendors in Europe is now a distinct possibility. Dr. Alexander Radbruch, head of neuro-oncologic imaging at the German Cancer Research Center in Heidelberg and University Hospital Essen, is both a lawyer and a radiologist, and he presents his views and ideas on this controversial topic.